--- title: Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer nct_id: NCT02054741 overall_status: COMPLETED phase: NA sponsor: Supriya Mohile study_type: INTERVENTIONAL primary_condition: Adult Solid Neoplasm countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02054741.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02054741" ct_last_update_post_date: 2024-04-12 last_seen_at: "2026-05-12T06:20:55.385Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer **Official Title:** A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults **NCT ID:** [NCT02054741](https://clinicaltrials.gov/study/NCT02054741) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 733 - **Lead Sponsor:** Supriya Mohile - **Collaborators:** National Cancer Institute (NCI), University of Chicago, City of Hope National Medical Center - **Conditions:** Adult Solid Neoplasm, Toxicity, Lymphoma - **Start Date:** 2014-07-29 - **Completion Date:** 2021-10-31 - **CT.gov Last Update:** 2024-04-12 ## Brief Summary This cluster randomized clinical trial compares a geriatric assessment intervention with usual care for reducing cancer treatment toxicity in older patients with cancer that has spread to other places in the body. A geriatric assessment may identify risk factors for cancer treatment toxicity and may improve outcomes for older patients with advanced cancer. ## Detailed Description PRIMARY OBJECTIVES: I. To determine if providing information regarding geriatric assessment (GA) and GA-driven recommendations to oncology physicians reduces clinician-rated grade 3-5 toxicity in patients aged 70 and over with advanced cancer starting a new treatment regimen. SECONDARY OBJECTIVES: I. Proportion of patients who are alive at 6 months after study entry. II. Evaluate whether providing oncology physicians with information regarding GA summary and GA-driven recommendations influences clinical care of older patients receiving treatment for advanced cancer. IIA. Compare treatment decisions (as measured by relative dose intensity of the agents administered in the first cycle). IIB. Describe the number and type of GA-driven recommendations implemented for older patients starting a new treatment regimen for advanced cancer. OUTLINE: Treatment sites are randomized to 1 of 2 arms. ARM I (GA intervention): Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations. ARM II (usual care): Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams. After completion of study, patients are followed up at 4-6 weeks, at 3 and 6 months, and at 1 year. ## Eligibility - **Minimum age:** 70 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * INCLUSION CRITERIA FOR PHYSICIANS * Oncology physicians must work at a National Cancer Institute (NCI) Community Oncology Research Program (NCORP) practice site with no plans to leave that NCORP practice site or retire at the time of enrollment into the study * INCLUSION CRITERIA FOR PATIENTS * Diagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; patients with a diagnosis of stage III cancer or lymphoma are eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowed * Plan to start a new cancer treatment regimen within 4 weeks from time of baseline registration; the treatment regimen is up to the discretion of the treating oncology physician; the regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity; patients who will receive monoclonal antibody therapy or other cancer therapies (e.g., tyrosine kinase inhibitors) are eligible if other agents present a prevalence of toxicity similar to chemotherapy; patients who are receiving approved cancer treatment in combination with radiation are eligible; a patient may also be enrolled on a treatment trial and participate in this study, if all other inclusion and exclusion criteria are met. \*Chemotherapy is defined as cytotoxic drugs; in addition, agents (e.g., monoclonal antibodies and targeted agents) that have a prevalence of grade 3-5 toxicity in older patients similar to chemotherapy (\>50%) will be allowed. * Plan to be on chemotherapy or other allowable treatment for at least 3 months (minimum 70 days) and be willing to come in for study visits * Have at least one geriatric assessment domain meet the cut-off score for impairment other than polypharmacy * Able to provide informed consent, or if the oncology physician determines the patient to not have decision-making capacity, a patient-designated health care proxy (or authorized representative per institutional policies) must sign consent by the baseline visit. If the participant is found to be impaired on the Blessed-Orientation Memory Concentration Test (BOMC) during screening; they must have a health care proxy or authorized representative to be eligible to enroll. * Participant has adequate understanding of the English language Exclusion Criteria: * EXCLUSION CRITERIA FOR PATIENTS * Have surgery planned within 3 months of consent; patients who have previously received surgery are eligible * Presence of symptomatic brain metastases at time of study consent process. Patients with a history of treated brain metastases are eligible if they are not symptomatic at the time of study enrollment. ``` ## Arms - **Arm I (GA intervention)** (EXPERIMENTAL) — Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations. - **Arm II (usual care)** (NO_INTERVENTION) — Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams. ## Interventions - **Comprehensive Geriatric Assessment** (OTHER) — Complete geriatric assessment - **Quality-of-Life Assessment** (OTHER) — Ancillary studies - **Survey Administration** (OTHER) — Ancillary studies ## Primary Outcomes - **Patient Experienced Any Grade 3-5 Toxicity** _(time frame: 3 months)_ — Proportion of patients who experienced grade 3-5 toxicity within 3 months of initiation of new treatment regimen. Toxicity was graded according to the National Cancer Institute (NCI) CTCAE version (v)4.0. ## Secondary Outcomes - **Patient Survival at 6 Months** _(time frame: 6 months)_ - **Reduced Dose Intensity** _(time frame: 4-6 weeks)_ - **GA-driven Recommendations Made Among Patients With Impaired Physical Performance.** _(time frame: Baseline)_ - **GA-driven Recommendations Made Among Patients With Impaired Functional Status.** _(time frame: Baseline)_ - **GA-driven Recommendations Made Among Patients With Impaired Comorbidities.** _(time frame: Baseline)_ - **GA-driven Recommendations Made Among Patients With Impaired Cognition.** _(time frame: Baseline)_ - **GA-driven Recommendations Made Among Patients With Impaired Nutrition.** _(time frame: Baseline)_ - **GA-driven Recommendations Made Among Patients With Impaired Social Support.** _(time frame: Baseline)_ - **GA-driven Recommendations Made Among Patients With Impaired Polypharmacy.** _(time frame: Baseline)_ - **GA-driven Recommendations Made Among Patients With Impaired Psychological Status.** _(time frame: Baseline)_ ## Locations (23) - City of Hope, Duarte, California, United States - Delaware/Christiana Care NCORP, Newark, Delaware, United States - Hawaii MU-NCORP, Honolulu, Hawaii, United States - University of Chicago, Chicago, Illinois, United States - Heartland NCORP, Decatur, Illinois, United States - Kansas City NCORP, Prairie Village, Kansas, United States - Wichita NCORP, Wichita, Kansas, United States - Gulf South MU-NCORP, New Orleans, Louisiana, United States - Cancer Research Consortium of West Michigan, Grand Rapids, Michigan, United States - Metro Minnesota NCORP, Minneapolis, Minnesota, United States - Kansas City NCORP, Kansas City, Missouri, United States - Nevada NCORP, Las Vegas, Nevada, United States - North Shore LIJ Health System NCORP, Lake Success, New York, United States - University of Rochester, Rochester, New York, United States - Southeast Clinical Oncology Research Program, Winston-Salem, North Carolina, United States - Columbus NCORP, Columbus, Ohio, United States - Dayton NCORP, Dayton, Ohio, United States - Pacific Cancer Research Consortium Ncorp, Portland, Oregon, United States - Geisinger Cancer Institute NCORP, Danville, Pennsylvania, United States - NCORP of the Carolinas, Greenville, South Carolina, United States - Northwest NCORP, Tacoma, Washington, United States - Wisconsin NCORP, Marshfield, Wisconsin, United States - Aurora NCORP, Milwaukee, Wisconsin, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.city of hope|duarte|california|united states` — added _(2026-05-12)_ - `locations.delaware/christiana care ncorp|newark|delaware|united states` — added _(2026-05-12)_ - `locations.hawaii mu-ncorp|honolulu|hawaii|united states` — added _(2026-05-12)_ - `locations.university of chicago|chicago|illinois|united states` — added _(2026-05-12)_ - `locations.heartland ncorp|decatur|illinois|united states` — added _(2026-05-12)_ - `locations.kansas city ncorp|prairie village|kansas|united states` — added _(2026-05-12)_ - `locations.wichita ncorp|wichita|kansas|united states` — added _(2026-05-12)_ - `locations.gulf south mu-ncorp|new orleans|louisiana|united states` — added _(2026-05-12)_ - `locations.cancer research consortium of west michigan|grand rapids|michigan|united states` — added _(2026-05-12)_ - `locations.metro minnesota ncorp|minneapolis|minnesota|united states` — added _(2026-05-12)_ - `locations.kansas city ncorp|kansas city|missouri|united states` — added _(2026-05-12)_ - `locations.nevada ncorp|las vegas|nevada|united states` — added _(2026-05-12)_ - `locations.north shore lij health system ncorp|lake success|new york|united states` — added _(2026-05-12)_ - `locations.university of rochester|rochester|new york|united states` — added _(2026-05-12)_ - `locations.southeast clinical oncology research program|winston-salem|north carolina|united states` — added _(2026-05-12)_ - `locations.columbus ncorp|columbus|ohio|united states` — added _(2026-05-12)_ - `locations.dayton ncorp|dayton|ohio|united states` — added _(2026-05-12)_ - `locations.pacific cancer research consortium ncorp|portland|oregon|united states` — added _(2026-05-12)_ - `locations.geisinger cancer institute ncorp|danville|pennsylvania|united states` — added _(2026-05-12)_ - `locations.ncorp of the carolinas|greenville|south carolina|united states` — added _(2026-05-12)_ - `locations.northwest ncorp|tacoma|washington|united states` — added _(2026-05-12)_ - `locations.wisconsin ncorp|marshfield|wisconsin|united states` — added _(2026-05-12)_ - `locations.aurora ncorp|milwaukee|wisconsin|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02054741.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02054741* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*